Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma
NCI Definition: A rare, keratinizing or non-keratinizing squamous cell carcinoma arising from the mucosal epithelium of the nasal cavity or the paranasal sinuses. It affects most often the maxillary sinus. Less frequently, it arises from the nasal cavity, ethmoid sinus, sphenoid sinus, and frontal sinus. Symptoms include nasal fullness, epistaxis, rhinorhea, pain, and paresthesia. Patients with nasal squamous cell carcinoma usually present earlier than patients with maxillary sinus carcinoma and have a better prognosis compared to the latter group. 
Nasal cavity and paranasal sinus squamous cell carcinomas most frequently harbor alterations in TP53, PTEN, CDKN2A, PIK3CA, and KMT2D .
TP53 Mutation, TP53 Nonsense, PTEN Mutation, PIK3CA Mutation, and KMT2D Mutation are the most common alterations in nasal cavity and paranasal sinus squamous cell carcinoma .
There are 3 clinical trials for nasal cavity and paranasal sinus squamous cell carcinoma, of which 3 are open and 0 are completed or closed. Of the trials that contain nasal cavity and paranasal sinus squamous cell carcinoma as an inclusion criterion, 3 are phase 2 (3 open).
Cisplatin, docetaxel, and etoposide are the most common interventions in nasal cavity and paranasal sinus squamous cell carcinoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.